Profound Named 2015 Beauty Breakthrough

Non-Surgical Treatment Creates Younger Skin Profoundly

Dec 23, 2015, 10:22 ET from Syneron

IRVINE, Calif., Dec. 23, 2015 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, is proud to announce that its revolutionary Profound® non-surgical radiofrequency micro-needle device with proprietary and patent protected technology, has been hailed one of 2015's biggest aesthetic breakthroughs by Yahoo! Beauty and Plastic Surgery Practice Magazine.

Plastic Surgery Practice Magazine calls Profound one of the Four Hottest Launches in 2015, highlighting its ability to lift sagging jowls, define the jawline, and add volume to marionette lines, all without surgery.

Yahoo! Beauty also publicized the exciting possibilities of the new treatment, naming it one of "The Seven Biggest Beauty Breakthroughs in 2015".

"With Profound, physicians deliver maximum results with minimum downtime, empowering the creation of younger, smoother skin with unprecedented outcomes," says Amit Meridor, Chief Executive Officer of Syneron. "We are delighted to receive recognition from the leading experts at Yahoo! and Plastic Surgery Practice, and honored to be featured among treatments that revolutionize the way we combat aging."

What Profound Does
Profound is changing the way consumers and doctors think about combating the signs of aging. Results suggest that with optimal settings, one Profound treatment restores volume1 creating younger2 looking skin. The system delivers radiofrequency energy through micro-needles to boost collagen, elastin, and hyaluronic acid from the inside out and is clinically proven to improve facial wrinkles.

"It's a whole new chapter in lasers," explains Macrene Alexiades, MD, PhD, Associate Clinical Professor at Yale University School of Medicine. "It's the closest we have gotten to a surgical facelift, non-surgically." 

Profound delivers energy directly into the deep dermis to stimulate the production of elastin, collagen, and hyaluronic acid, the three key building blocks for youthful skin. As a result, the treatment adds volume and resiliency to the jawline, neck, jowls, nasolabial folds and cheeks. It is ideal for women and men who are seeking a non-surgical, minimally invasive treatment to look younger.

The results are the culmination of a decade of research which used Syneron's patented and proprietary Profound micro-needle-based radiofrequency energy delivery system with precise, real time, temperature control within the skin. The study arm that used optimal treatment parameters settings resulted in a 100% response rate3 among all subjects treated as assessed by blinded evaluation. 

Unlike facelifts, which require general anesthesia, long incisions, and recovery, Profound patients typically experience only minor redness that resolves within two to 12 hours and minimal swelling for up to five days. Most patients can resume normal activities within 24-48 hours. Only one treatment is needed4.

About Syneron Candela
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint.  The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, Profound and elos Plus.

Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S.  The company markets, services and supports its products in 86 countries.  It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

For additional information, please visit http://www.syneron-candela.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including product efficacy, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

1Bipolar Fractional Radiofrequency Treatment Induces Neoelastogenesis and Neocollagenesis. Hantash, Basil et al. Lasers in Surgery and Medicine, 2009.

2 Based on results of a clinical study in 20 patients, measuring improvement in Fitzpatrick Wrinkle Scale at 3 months compared to baseline on independent review of photographs.

3 Data on file.

4 Prospective Multicenter Clinical Trial of a Minimally Invasive Temperature-Controlled Bipolar Fractional Radiofrequency System for Rhytid and Laxity Treatment, Alexiades-Armenakas, Macrene et al. Dermatologic Surgery, 2012

Contacts:
Syneron Medical – Public Relations
pr@syneron.com 

KELZ PR 
Melissa Ben-YosephMelissa@kelzpr.com 
Sheila Arwaysheila@kelzpr.com 
646-450-5359

Logo - http://photos.prnewswire.com/prnh/20120528/535447 

SOURCE Syneron



RELATED LINKS

http://www.syneron-candela.com